BlueHealer Developed New Tibial Transverse Transport Tool
The Baltimore startup is designing an internal device to help prevent non-traumatic lower-limb amputations.
Updated on Oct. 9, 2026 in Diabetes
Live Poll
Do you trust that medical innovation is currently making healthcare safer and more accessible for you?
Startup BlueHealer is developing an internal medical device to perform Tibial Transverse Transport (TTT) surgery. The project aims to provide a safer alternative to the current external frames used to improve blood flow in patients suffering from arterial disease and diabetes.
Why it matters
Diabetes and arterial disease cause most non-traumatic amputations in the United States, yet current bone-moving techniques using external frames carry risks of infection and fractures. By moving the process internally, the device seeks to reduce these complications for high-risk patient populations.
Approximately 150,000 Americans undergo lower-limb amputations annually, with Black patients and less affluent individuals with diabetes four times as likely to lose a limb. Tibial Transverse Transport is currently performed in over 10 countries using external frames.
The players
BlueHealer
This Baltimore-based startup is currently designing an internal device to improve Tibial Transverse Transport surgical outcomes.
Johns Hopkins University
This Baltimore-based institution served as the site for initial research into the Tibial Transverse Transport process.
The details
The procedure involves cutting and moving a small section of the tibia to stimulate blood flow in the affected limb. BlueHealer is designing an internal device to perform this movement, aiming to bypass the infection and fracture risks associated with traditional external metal frames.
Timeline
In 2024, cofounders pitched the TTT process at Johns Hopkins University.
In September 2026, Foot and Ankle News characterized the growth of TTT surgeries as a gold rush.
The Big Picture
This story follows the pattern of increased interest identified in the 2026 Foot and Ankle News classification of TTT as a gold rush. The emergence of new internal devices signifies a broader industry shift toward minimizing the infection risks associated with legacy external bone-frame technologies.
The development of internal devices could eventually provide patients suffering from diabetes-related arterial disease with a lower-risk alternative to traditional amputation surgeries. This innovation aims to reduce the post-surgical complications that currently affect patients using external frames.
The takeaway
Advancements in internal bone-transport technology aim to bridge the significant disparity in amputation rates among vulnerable populations. Moving away from external frames could fundamentally improve patient recovery timelines and long-term health outcomes for those battling limb-threatening conditions.
Further reading
For more on evolving treatment options, visit the Diabetes section.
Source note: This article includes information reported by Technical.
Live Poll
Do you trust that medical innovation is currently making healthcare safer and more accessible for you?
